Using lipid nanoparticles to improve CAR T cell cancer treatment

Lipid nanoparticles (LNPs) may enhance the production process of chimeric antigen receptor (CAR) T cells.

• LNPs can activate T cells and deliver the CAR transgene simultaneously, potentially streamlining CAR T cell production.
• Current CAR T cell production methods have limitations that LNPs could help to address.
• The review highlights recent advancements in LNP designs aimed at improving CAR T cell therapy.
• Safety, immunogenicity, scalability, manufacturing, and regulatory considerations are crucial for the clinical application of LNP-based CAR T cell therapies.

Simplified